iPSC-Derived Multilineage Organoids: A New Era for Hepatitis E Virus Research

Study Background and Research Question

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis globally, yet research into its lifecycle and pathogenesis has been hampered by the lack of physiologically relevant in vitro models. Traditional systems, such as hepatoma cell lines and adult tissue-derived organoids, have shown limited capacity to support wild-type HEV infection, restricting their utility for studying viral tropism and host responses. This limitation is particularly significant given HEV's demonstrated ability to infect not only hepatocytes but also extrahepatic tissues, including the intestine and nervous system (reference study). The primary research question addressed by Liu et al. (2025) is whether induced pluripotent stem cell (iPSC)-derived multilineage human organoids can serve as robust, pan-genotype infection models for HEV, enabling comprehensive investigation of viral propagation and host-pathogen interactions.

Key Innovation from the Reference Study

The central innovation lies in the establishment of iPSC-induced liver, intestinal, and brain organoid platforms (hLOs, hIOs, hBOs) that collectively recapitulate the complexity of human tissue architecture and function. Unlike previous models, these multilineage organoids support the complete life cycle of wild-type HEV genotypes 1, 3, and 4. This approach not only reveals expanded viral tropism—demonstrating productive infection in hepatocytes, cholangiocytes, hepatic macrophages, stellate cells, diverse intestinal epithelial and mesenchymal cells, as well as multiple neuronal subtypes—but also allows for the study of HEV-induced tissue-specific injury and immune responses (reference study).

Methods and Experimental Design Insights

The researchers generated multilineage organoids from human iPSCs using defined differentiation protocols, producing liver organoids containing hepatocytes, cholangiocytes, macrophages, and stellate cells; intestinal organoids with enterocytes, goblet, Paneth, and endocrine cells; and brain organoids comprising glutamatergic, dopaminergic, and GABAergic neurons, astrocytes, and oligodendrocytes. Organoids were challenged with clinical isolates of HEV genotypes 1, 3, and 4 to assess susceptibility, viral propagation, and host responses. The team evaluated infection via immunostaining, RT-qPCR for viral RNA, and assessment of functional and injury biomarkers—such as albumin and Factor IX secretion (liver), tight junction integrity (intestine), and neuronal subpopulation changes (brain). The antiviral effect of ribavirin was tested to validate the system's utility for drug screening.

Protocol Parameters

• Organoid infection: Inoculation with clinical HEV isolates (genotypes 1, 3, 4); multiplicity of infection tailored to tissue type and cell density.
• Assessment of infection: Immunostaining for HEV antigens; RT-qPCR for quantification of viral RNA.
• Functional assays: Measurement of albumin and Factor IX (liver), evaluation of tight junction proteins (intestine), and neuronal cell marker analysis (brain).
• Drug testing: Application of ribavirin at clinically relevant concentrations; assessment of partial phenotype rescue in all three organoid types.

Core Findings and Why They Matter

All three organoid types supported productive HEV infection, covering the full viral life cycle. In liver organoids, HEV infected not only established targets (hepatocytes, cholangiocytes, macrophages) but also hepatic stellate cells—a previously underexplored reservoir. Infection led to elevated interleukin-6, impaired hepatic function, and biomarkers indicative of hepatocellular injury. In intestinal organoids, the virus exhibited broad epithelial and mesenchymal tropism, disrupting barrier integrity through loss of tight junction proteins and induction of epithelial–mesenchymal transition. Brain organoids revealed neuronal tropism, with infection in multiple neuronal and glial subtypes, and a notable increase in dopaminergic neurons—an effect only partially reversed by ribavirin. These findings demonstrate that HEV can produce tissue-specific injury and immune responses across organ systems (reference study). The ability to model sequential gut–liver–gut infection further enhances the physiological relevance of the platform.

Comparison with Existing Internal Articles

Prior internal reviews have highlighted the transformative impact of iPSC-derived organoid models for HEV research. For instance, the article "iPSC-Derived Organoid Models Advance Hepatitis E Virus Research" reinforces the current study's demonstration of robust, multitissue HEV propagation. Another perspective, "iPSC-Derived Organoids Enable Pangenotype HEV Research", contextualizes these organoids as physiologically relevant tools for dissecting viral pathogenesis and evaluating antivirals. Compared to previous reports, the reference study advances the field by providing experimental evidence of expanded cellular tropism (notably hepatic stellate cells and diverse neuronal subtypes), and by functionally linking infection to tissue-specific injury mechanisms and partial pharmacological rescue. This integrated, multitissue platform bridges gaps left by earlier mono-tissue or cell line systems.

Limitations and Transferability

While iPSC-derived organoids offer significant advantages in recapitulating human tissue complexity, several limitations remain. Organoid systems, though multicellular, cannot fully mimic the vascularization, immune cell diversity, and microenvironmental cues of in vivo tissues. Batch variability in differentiation and organoid maturation may affect reproducibility. Furthermore, while the study successfully models pan-genotype HEV infection and response to ribavirin, its generalizability to all clinical isolates or to chronic infection states remains to be demonstrated. Transferability to other viral pathogens or pharmacological classes should be approached with caution and validated experimentally.

Why this cross-domain matters, maturity, and limitations

The use of organoid models as surrogates for animal testing aligns with recent regulatory shifts, such as the FDA's move to reduce animal requirements in antiviral drug evaluation. This cross-domain application not only accelerates mechanistic studies of HEV but also provides a testbed for preclinical drug screening. However, while organoids facilitate a reduction in animal use, further validation against clinical and in vivo data is essential before broad translational adoption.

Research Support Resources

Researchers aiming to model antiviral responses or test apoptosis inducers in organoid systems may benefit from high-purity reagents characterized in similar workflows. Vitamin C (CAS 50-81-7) (SKU B2064) from APExBIO is a well-characterized water-soluble vitamin with documented efficacy as an apoptosis inducer and inhibitor of tumor cell proliferation in organoid and in vivo models, supporting both cancer and antiviral research. When designing experiments involving oxidative stress modulation or evaluating antiviral agents, this reagent’s stability, purity, and solubility benchmarks are advantageous. Protocols and mechanistic insights for integrating Vitamin C into iPSC-derived organoid workflows are discussed in detail in the article "Vitamin C (CAS 50-81-7): Advanced Applications in Cancer and Antiviral Organoid Models". As with all experimental designs, solutions should be freshly prepared and used promptly to ensure optimal stability.